In recent years, the mainland has established stem cell and regenerative medicine research as an important strategic deployment, and has given strong support to its basic research, key technologies, resource platform construction and industrialization development. As a leading enterprise in Hunan Province that has been deeply cultivating the stem cell industry for many years, Nanhua Biopharmaceutical Co., Ltd. (hereinafter referred to as "Nanhua Biopharma"), a state-owned listed enterprise, has made a key layout in the field of stem cell regenerative medicine.
The state and local governments support the development of stem cell regenerative medicine
Since the "Twelfth Five-Year Plan", through the National Key Basic Research and Development Program, the High-tech Research and Development Program, the National Natural Science Foundation of China, etc., it has continuously strengthened the funding intensity in the field of stem cells and regenerative medicine, and has invested more than 4 billion yuan to support related research. "Stem cell research and organ repair" was also listed as the first batch of key special tasks launched by the "14th Five-Year Plan" National Key Research and Development Program.
Stem cell regenerative medicine is in line with the economic development strategy of "three highs and four new" in Hunan Province, and has important scientific significance and broad application prospects. The "Hunan Provincial Health Industry Development Plan (2016-2020)", the "13th Five-Year Plan for Scientific and Technological Innovation in Hunan Province", and the "14th Five-Year Plan for Healthy Hunan" have all deployed the development of stem cell technology and the promotion of major drug industrialization. In January 2022, during the two sessions of Hunan Province, Wu Jinming, Kong Heping, Chen Hongzhong and Zheng Ansheng, members of the Provincial Committee of the Chinese People's Political Consultative Conference, jointly proposed to support the development of The Stem Cell and Regenerative Medicine Industry Cluster in Hunan.
Construction of "Stem Cell Regenerative Medicine and Reproductive Health" industry-university-research base
In 2021, Hunan Boai Kangmin Stem Cell Tissue Engineering Co., Ltd., a wholly-owned subsidiary of Nanhua Biologics, signed an agreement with Changsha Maternal and Child Health Hospital and Hunan Normal University to jointly build a demonstration base for industry-university-research cooperation on "Stem Cell Regenerative Medicine and Reproductive Health". On January 10, 2022, He Jun, vice president of Changsha Maternal and Child Health Hospital, Hu Xiang, associate professor of Hunan Normal University, and Wu Le, general manager of Hunan Boai Kangmin Stem Cell Tissue Engineering Co., Ltd., unveiled the "Stem Cell Regenerative Medicine and Reproductive Health" industry-university-research cooperation demonstration base and officially started construction.
Based on the advanced stem cell regenerative medicine research technology platform and achievements of Hunan Normal University and the mature stem cell drug research and development and industrialization platform of Hunan Boai Kangmin Stem Cell Tissue Engineering Co., Ltd., the "Stem Cell Regenerative Medicine and Reproductive Health" industry-university-research cooperation demonstration base integrates the superior resources and clinical technologies of Changsha Maternal and Child Health Hospital in the field of reproductive health, and fully integrates and utilizes the "973" and "863" research results through the "small institution, big network" industry-university-research cooperation model. Accelerate the process of engineering and industrialization of stem cell regenerative medicine research and development results.
Stem Cell Regenerative Medicine and Reproductive Health
Reproductive health is related to the health of the population, and surveys in recent years have shown that the reproductive health of women on the mainland is not optimistic. According to statistics, the number of infertility patients in the mainland exceeds 50 million people, of which 20%-40% are caused by endometrial damage, infertility caused by premature ovarian failure accounts for 15%-25%, and the number and incidence of infertility are increasing and becoming younger. Under the national policy of "fully liberalizing the three children", the number of pregnant women with advanced age and scars in the uterus and the number of menstruating women also showed an upward trend, and the incidence of pregnancy complications such as placental implantation, preeclampsia, and gestational diabetes also increased.
Clinical studies have shown that stem cells have the potential to regenerate a variety of cells, can comprehensively repair damaged tissues from the cell level, and also have a strong immunomodulatory effect to reduce the inflammatory response, improve the pathological microenvironment, provide a new entry point for the clinical treatment of refractory diseases in women's obstetrics and gynecology, and are of great significance for improving and caring for women's reproductive health. Up to now, in the field of reproductive health, 13 clinical research projects related to ovarian insufficiency and endometrial damage have been completed for the record of the Health Commission, most of which use umbilical cord-derived mesenchymal stem cells.
"Stem Cell Regenerative Medicine and Reproductive Health" Industry-University-Research Cooperation Demonstration Base will mainly focus on stem cell regenerative medicine technology in the field of obstetrics and reproductive health to carry out relevant scientific research projects in the field of obstetrics and reproductive health, such as stem cells to improve ovarian function, repair endometrial damage and other aspects of basic and clinical application research, the development of stem cell by-products combined with biological materials series of products for postpartum repair, etc.; another research direction is the establishment of standardized obstetric biological sample bank, through the establishment of obstetric sample collection, Quality control and information standardization processes and standardized management to achieve early warning, early screening, diagnosis and treatment of pregnancy and genetic diseases.
The four major scientific research transformation platforms of South China Biology
At present, the scientific research transformation platform of Nanhua Bio has formed a four-legged development trend. In addition to the "Stem Cell Regenerative Medicine and Reproductive Health" industry-university-research cooperation demonstration base, it also has the Hunan Clinical Research Center of the National Stem Cell Transformation Resource Bank, the National and Local Joint Engineering Laboratory for Animal Peptide Drug Creation, and the South China Institute of Biomedicine in Hunan Province.
Nanhua Biologics will give full play to the advantages of the state-owned main board listed companies, through improving the construction of scientific research platforms, upgrading scientific research and technological strength, strengthening scientific and technological transformation results, realizing the combination of platforms and projects, seizing the commanding heights of biomedical research and development and production, contributing to the in-depth implementation of the "three highs and four new" strategy, and injecting new impetus into the national stem cell regenerative medicine technology innovation.